Joseph Shulman has sold RYTM and made no open-market buys since Feb 2023

Joseph (Joe) Shulman is a corporate insider and Chief Technical Officer at Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM), a biopharmaceutical company focused on treatments for rare genetic forms of obesity.( He joined Rhythm in July 2020 as Senior Vice President of Technical Operations and was subsequently promoted to Chief Technical Officer in 2022, bringing more than 20 years of industry experience to the role.( As CTO, Shulman is responsible for chemistry, manufacturing, and controls (CMC), clinical and commercial supply chains, and cGMP quality assurance and quality control, supporting the global development and commercialization of Rhythm’s lead product, IMCIVREE (setmelanotide).(

Prior to joining Rhythm Pharmaceuticals, Shulman held senior technical and operations leadership roles in the pharmaceutical and medical device sectors, including work in areas such as renal research and complex clinical supply chains.( As a reporting insider under U.S. securities laws, he has executed multiple Form 4-reported transactions in Rhythm Pharmaceuticals stock, reflecting ongoing equity-based participation in the company’s performance.( Public filings indicate that Shulman is based in the greater Boston, Massachusetts area, where Rhythm maintains its corporate headquarters.(

Written by Perplexity from public sources.